Literature DB >> 20841423

CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.

Fatih M Uckun1, Patricia Goodman, Hong Ma, Ilker Dibirdik, Sanjive Qazi.   

Abstract

Here, we report that primary leukemic cells from infants with newly diagnosed B-precursor leukemia express a truncated and functionally defective CD22 coreceptor protein that is unable to transmit apoptotic signals because it lacks most of the intracellular domain, including the key regulatory signal transduction elements and all of the cytoplasmic tyrosine residues. Expression of this structurally and functionally abnormal CD22 protein is associated with a very aggressive in vivo growth of patients' primary leukemia cells causing disseminated overt leukemia in SCID mice. The abnormal CD22 coreceptor is encoded by a profoundly aberrant mRNA arising from a splicing defect that causes the deletion of exon 12 (c.2208-c.2327) (CD22ΔE12) and results in a truncating frameshift mutation. The splicing defect is associated with multiple homozygous mutations within a 132-bp segment of the intronic sequence between exons 12 and 13. These mutations cause marked changes in the predicted secondary structures of the mutant CD22 pre-mRNA sequences that affect the target motifs for the splicing factors hnRNP-L, PTB, and PCBP that are up-regulated in infant leukemia cells. Forced expression of the mutant CD22ΔE12 protein in transgenic mice perturbs B-cell development, as evidenced by B-precursor/B-cell hyperplasia, and corrupts the regulation of gene expression, causing reduced expression levels of several genes with a tumor suppressor function. We further show that CD22ΔE12-associated unique gene expression signature is a discriminating feature of newly diagnosed infant leukemia patients. These striking findings implicate CD22ΔE12 as a previously undescribed pathogenic mechanism in human B-precursor leukemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20841423      PMCID: PMC2947921          DOI: 10.1073/pnas.1007896107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  62 in total

1.  SH2 domains recognize specific phosphopeptide sequences.

Authors:  Z Songyang; S E Shoelson; M Chaudhuri; G Gish; T Pawson; W G Haser; F King; T Roberts; S Ratnofsky; R J Lechleider
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

2.  Analysis of murine CD22 during B cell development: CD22 is expressed on B cell progenitors prior to IgM.

Authors:  A Stoddart; R J Ray; C J Paige
Journal:  Int Immunol       Date:  1997-10       Impact factor: 4.823

3.  CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice.

Authors:  S Sato; A S Miller; M Inaoki; C B Bock; P J Jansen; M L Tang; T F Tedder
Journal:  Immunity       Date:  1996-12       Impact factor: 31.745

4.  Genomic structure and chromosomal mapping of the human CD22 gene.

Authors:  G L Wilson; V Najfeld; E Kozlow; J Menniger; D Ward; J H Kehrl
Journal:  J Immunol       Date:  1993-06-01       Impact factor: 5.422

Review 5.  Leukemia in twins: lessons in natural history.

Authors:  Mel F Greaves; Ana Teresa Maia; Joseph L Wiemels; Anthony M Ford
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

6.  The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction.

Authors:  BinuJoy John; Brantley R Herrin; Chander Raman; Yan-ni Wang; Kevin R Bobbitt; Brian A Brody; Louis B Justement
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

7.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice.

Authors:  J M Adams; A W Harris; C A Pinkert; L M Corcoran; W S Alexander; S Cory; R D Palmiter; R L Brinster
Journal:  Nature       Date:  1985 Dec 12-18       Impact factor: 49.962

8.  A comprehensive in silico expression analysis of RNA binding proteins in normal and tumor tissue: Identification of potential players in tumor formation.

Authors:  Pedro A F Galante; Devraj Sandhu; Raquel de Sousa Abreu; Michael Gradassi; Natanja Slager; Christine Vogel; Sandro Jose de Souza; Luiz O F Penalva
Journal:  RNA Biol       Date:  2009-09-24       Impact factor: 4.652

9.  Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice.

Authors:  J Wang; T Koizumi; T Watanabe
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

10.  Aberrant splicing of the senataxin gene in a patient with ataxia with oculomotor apraxia type 2.

Authors:  Brent L Fogel; Ji Yong Lee; Susan Perlman
Journal:  Cerebellum       Date:  2009-12       Impact factor: 3.847

View more
  22 in total

1.  CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.

Authors:  Fatih M Uckun; Sanjive Qazi; Hong Ma; Gregory H Reaman; Lloyd G Mitchell
Journal:  Integr Biol (Camb)       Date:  2015-02       Impact factor: 2.192

Review 2.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

3.  Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.

Authors:  Fatih M Uckun; Dorothea E Myers; Sanjive Qazi; Zahide Ozer; Rebecca Rose; Osmond J D'Cruz; Hong Ma
Journal:  J Clin Invest       Date:  2015-01-26       Impact factor: 14.808

4.  CD22ΔE12 as a molecular target for RNAi therapy.

Authors:  Fatih M Uckun; Hong Ma; Jianjun Cheng; Dorothea E Myers; Sanjive Qazi
Journal:  Br J Haematol       Date:  2015-02-06       Impact factor: 6.998

5.  Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies.

Authors:  Jessie Bourcier; Omar Abdel-Wahab
Journal:  Blood Cancer Discov       Date:  2022-03-01

6.  Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.

Authors:  Ingrid Cely; Seang Yiv; Qian Yin; Anoush Shahidzadeh; Li Tang; Jianjun Cheng; Fatih M Uckun
Journal:  J Anal Oncol       Date:  2012-06-25

7.  Absence of Genomic Ikaros/IKZF1 Deletions in Pediatric B-Precursor Acute Lymphoblastic Leukemia.

Authors:  Sanjive Qazi; Hong Ma; Fatih M Uckun
Journal:  Int J Mol Med Sci       Date:  2013-07-29

8.  FAM190A rearrangements provide a multitude of individualized tumor signatures and neo-antigens in cancer.

Authors:  Francesca Scrimieri; Eric S Calhoun; Kalpesh Patel; Rigu Gupta; David L Huso; Ralph H Hruban; Scott E Kern
Journal:  Oncotarget       Date:  2011 Jan-Feb

9.  Regulation of B cell functions by the sialic acid-binding receptors siglec-G and CD22.

Authors:  Julia Jellusova; Lars Nitschke
Journal:  Front Immunol       Date:  2012-01-11       Impact factor: 7.561

10.  Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL.

Authors:  Fatih M Uckun; Lloyd G Mitchell; Sanjive Qazi; Yang Liu; Nan Zheng; Dorothea E Myers; Ziyuan Song; Hong Ma; Jianjun Cheng
Journal:  EBioMedicine       Date:  2015-04-30       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.